The Global Diabetic Macular Edema Market is experiencing significant growth driven by rising diabetes prevalence and technological advancements in retinal diagnostics like OCT and AI-enabled imaging.

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2025 adjusted earnings per share (EPS) of $11.44, which ...

REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive ...

In this Healio Video Perspective from Retina 2026, Ehsan Rahimy, MD, discusses the potential of IL-6 inhibition for the ...

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and ...

Managing your blood sugar and metabolic health is the top thing you can do to mitigate diabetes complications. Other ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript January 30, 2026 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $11.44, expectations were ...

These results suggest an important takeaway: how blood sugar is controlled matters. A nutrient-dense, plant-based diet that helps maintain healthy blood sugar levels may lower your risk of diabetic ...

PTI founder Imran Khan has been diagnosed with a serious eye disease called CRVO.Former Prime Minister Imran Khan has been ...

Alvotech now has worldwide rights to manufacture and supply its global commercial partners with the aflibercept biosimilar.

Regeneron Pharmaceuticals, Inc. Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus ...

William Blair analysts view Elevidys’ three-year outcome as a win, though remain sceptical on the readout’s impact on sales and uptake.